GLAXF News and Press, GlaxoSmithKline Plc From 01/14/24

2024-01-14 03:40:00 ET Summary Shanghai Argo Biopharma entered two agreements with Novartis for a total value of $4.2 billion. San Diego’s Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion. GSK plans to acquire Aiolos Bio, a San Francisco-London s...

2024-01-10 08:01:12 ET Summary Data readout from phase 2 GALAXIES Lung-201 study, using belrestotug in combination with dostarlimab to treat patients with 1st-line advanced/metastatic NSCLC, expected 2024. The global non-small cell lung cancer market is expected to reach $36.9 bil...

2024-01-09 18:04:24 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2024-01-09 14:38:04 ET GSK plc (GSK) 42nd Annual JP Morgan Healthcare Conference January 09, 2024 10:30 AM ET Company Participants Emma Walmsley - Chief Executive Officer Luke Miels - Chief Commercial Officer Tony Wood - Chief Scientific Officer Conference ...

2023-12-23 04:18:53 ET Summary AbbVie and GSK are both solid investment choices in the biopharmaceutical industry. AbbVie's financials and forward outlook show strong performance alongside solid partnerships, which hint at growth potential. GSK's current financials, product la...

2023-12-13 12:51:53 ET Summary GSK's diversified portfolio and high dividend yield make it an attractive option for conservative value portfolios. The company's pipeline of drugs is improving, with a significant increase in drugs in clinical development and strong financial result...

2023-12-05 22:50:05 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2023-11-30 12:52:09 ET GSK plc (GSK) Getting Ahead of Respiratory Diseases Event with GSK Management Conference Call November 30, 2023 08:00 ET Company Participants Nick Stone - Investor Relations Tony Wood - Chief Scientific Officer Luke Miels - Chief Commercial...

2023-11-29 15:16:06 ET GSK plc (GSK) Redburn Atlantic CEO Conference November 29, 2023 04:00 AM ET Company Participants Luke Miels - Chief Commercial Officer Conference Call Participants Simon Baker - Redburn Presentation Simon Baker Good ...

2023-11-29 15:00:01 ET Summary Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; as a result, shares are down over 20% year-over-y...